Evidence map›Paper›PMID 24782625›Full record

ArticleWorld journal of gastroenterology2014

MT1M and MT1G promoter methylation as biomarkers for hepatocellular carcinoma.

Xiang-Fen Ji, Yu-Chen Fan, Shuai Gao, Yang Yang, Jian-Jun Zhang, Kai Wang

Open access · hybridAbstract read
In one paragraph

Article in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 6 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 6 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2020
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Xiang-Fen JiXiang-Fen Ji, Shuai Gao, Yang Yang, Jian-Jun Zhang, Department of Hepatology, Qilu Hospital of Shandong University, Jinan 250012, Shandong Province, China.
Yu-Chen FanXiang-Fen Ji, Shuai Gao, Yang Yang, Jian-Jun Zhang, Department of Hepatology, Qilu Hospital of Shandong University, Jinan 250012, Shandong Province, China.
Shuai GaoXiang-Fen Ji, Shuai Gao, Yang Yang, Jian-Jun Zhang, Department of Hepatology, Qilu Hospital of Shandong University, Jinan 250012, Shandong Province, China.
Yang YangXiang-Fen Ji, Shuai Gao, Yang Yang, Jian-Jun Zhang, Department of Hepatology, Qilu Hospital of Shandong University, Jinan 250012, Shandong Province, China.
Jian-Jun ZhangXiang-Fen Ji, Shuai Gao, Yang Yang, Jian-Jun Zhang, Department of Hepatology, Qilu Hospital of Shandong University, Jinan 250012, Shandong Province, China.
Kai WangXiang-Fen Ji, Shuai Gao, Yang Yang, Jian-Jun Zhang, Department of Hepatology, Qilu Hospital of Shandong University, Jinan 250012, Shandong Province, China.
Qilu Hospital of Shandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the potential of promoter methylation of two tumor suppressor genes (TSGs) as biomarkers for hepatocellular carcinoma (HCC).

methodsA total of 189 subjects were included in this retrospective cohort, which contained 121 HCC patients without any history of curative treatment, 37 patients with chronic hepatitis B (CHB), and 31 normal controls (NCs). DNA samples were extracted from 400 μL of serum of each subject and then modified using bisulfite treatment. Methylation of the promoters of the TSGs (metallothionein 1M, MT1M; and metallothionein 1G, MT1G) was determined using methylation-specific polymerase chain reaction. The diagnostic value of combined MT1M and MT1G promoter methylation was evaluated using the area under the receiver operating characteristic curves.

resultsOur results indicated that the methylation status of serum MT1M (48.8%, 59/121) and MT1G (70.2%, 85/121) promoters in the HCC group was significantly higher than that in the CHB group (MT1M 5.4%, 2/37, P < 0.001; MT1G 16.2%, 6/37, P < 0.001) and NC group (MT1M 6.5%, 2/31, P < 0.001; MT1G 12.9%, 4/27, P < 0.001). Aberrant serum MT1M promoter methylation gave higher specificity to discriminate HCC from CHB (94.6%) and NCs (93.5%), whereas combined methylation of serum MT1M and MT1G promoters showed higher diagnostic sensitivity (90.9%), suggesting that they are potential markers for noninvasive detection of HCC. Furthermore, MT1M promoter methylation was positively correlated with tumor size (rs = 0.321, P < 0.001), and HCC patients with both MT1M and MT1G promoter methylation tended to show a higher incidence of vascular invasion or metastasis (P = 0.018).

conclusionMT1M and MT1G promoter methylation may be used as serum biomarkers for noninvasive detection of HCC.

Indexed as

DNA MethylationGenetic TestingPromoter Regions, GeneticArea Under CurveBiomarkers, TumorCarcinoma, HepatocellularFemaleHumansLiver NeoplasmsMaleMetallothioneinMiddle AgedPolymerase Chain ReactionPredictive Value of TestsPrognosisRetrospective StudiesBiomarkers, TumorMetallothioneinMT1G protein, humanMT1M protein, humanHepatocellular carcinomaMethylationMT1GMT1MSerum biomarker

Identifiers

PMID24782625
PMCPMC4000509
OpenAlexW2077852082

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.